Crossject SA (CRJTF) Gets a Hold Rating from Kepler Capital
Kepler Capital analyst David Evans maintained a Hold rating on Crossject SA (CRJTF) on June 8 and set a price target of EUR3.60. The company’s shares closed last Tuesday at $3.25, equals to its 52-week low of $3.25.
According to TipRanks.com, Evans is a 4-star analyst with an average return of 8.7% and a 67.3% success rate. Evans covers the Healthcare sector, focusing on stocks such as Quantum Genomics, Innate Pharma, and Pharnext SA.
Currently, the analyst consensus on Crossject SA is a Hold with an average price target of $4.38.
See today’s analyst top recommended stocks >>
Crossject SA’s market cap is currently $77.66M and has a P/E ratio of -6.50. The company has a Price to Book ratio of -7.42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CROSSJECT manufactures and markets needle-free drug self-injection system.